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Abstract
It has been recognized that molecular classifications will form the basis for neuropathologi-
cal diagnostic work in the future. Consequently, in order to reach a diagnosis of Alzheimer’s
disease (AD), the presence of hyperphosphorylated tau (HP-tau) and b-amyloid protein in
brain tissue must be unequivocal. In addition, the stepwise progression of pathology needs
to be assessed. This paper deals exclusively with the regional assessment of AD-related
HP-tau pathology. The objective was to provide straightforward instructions to aid in the
assessment of AD-related immunohistochemically (IHC) detected HP-tau pathology and to
test the concordance of assessments made by 25 independent evaluators. The assessment of
progression in 7-mm-thick sections was based on assessment of IHC labeled HP-tau immu-
noreactive neuropil threads (NTs). Our results indicate that good agreement can be reached
when the lesions are substantial, i.e., the lesions have reached isocortical structures (stage
V–VI absolute agreement 91%), whereas when only mild subtle lesions were present the
agreement was poorer (I–II absolute agreement 50%). Thus, in a research setting when the
extent of lesions is mild, it is strongly recommended that the assessment of lesions should
be carried out by at least two independent observers.
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INTRODUCTION
Alzheimer’s disease (AD)-related pathology, both neuritic plaques
(NP) and neurofibrillary tangles (NFT) is commonly seen in aged
subjects, both in neurologically unimpaired as well as in the
demented, as was already reported by Tomlinson and colleagues
in 1968 and 1970 (20,21). Consequently, before one can make a
definite diagnosis of AD, certain clinical symptoms as well as
disease-specific pathology should be present. The common view is
that if one wishes to obtain an exact and reproducible diagnosis in
an aged subject, this requires a detailed assessment of both clinical
and neuropathological phenotype. This paper deals solely with the
latter topic, that is, the neuropathological assessment of AD-related
neurofibrillary lesions seen in aged and demented individuals.
There are many prerequisites before one can issue consensus
recommendations for neuropathological diagnostic criteria. They
have to be applicable for routine working conditions and also to be
economical. They have to be widely acceptable, as well as repro-
ducible and reliable for use, and moreover, they have to be compre-
hensible and simple. Furthermore, using current recommenda-
tions, rather than relatively nonspecific chemical stains, these kinds
of criteria should have a molecular basis (1).
The first published consensus guidelines regarding assessment
of AD-related hallmark lesions, NP and NFT, were discussed in a
workshop jointly sponsored by the National Institute of Aging, the
American Association of Retired Persons, the National Institute of
Neurological and Communicative Disorders and Stroke and the
National Institute of Mental Health. As a result, Khatchaturian (9)
published a report in 1985 where recommendations were issued
regarding sampling of tissue, methods to be used, and the assess-
ment of lesions (Figure 1A). The emphasis was placed on the quan-
titative assessment of both NP and NFT in relation to the age of the
patient together with the clinical history that influenced the assess-
ment outcome or diagnosis (Figure 1A). The quantification of the
hallmark lesions, however, proved to be more complicated than
expected. In 1990, a European multicentre study under the auspices
of the European Community’s Concerted Action Programme on
Ageing and Diseases (EURAGE) reported that when assessing the
lesions typical of AD numerous staining techniques were used by
the 11 participating laboratories, and thus, it was not surprising that
the concordance between 11 investigators assessing NP and NFT
was poor (7). In the following year, the Consortium to Establish a
Registry for Alzheimer’s disease known by the acronym the
CERAD, launched revised instructions (Figure 1B) (12). CERAD
defined in more detail one of the hallmark lesions, that is, NP and
narrowed down the section thickness. They also provided instruc-
tions regarding the staining to be used and a schematic presentation
of the scoring of NP to facilitate reproducibility between different
centers. The simplicity and clarity of these instructions meant that
they soon acquired a wide number of users (12).
The main problem concerning the CERAD strategy is related
to the methodologies being used. The recommended fluorescent
thioflavine S preparation is viewed under ultraviolet light and thus
requires special equipment, not always available in all laboratories.
The recommended silver technique such as the modified
Bielschowsky method is somewhat laborious and capricious,
requires a well-trained technician and is influenced by ambient
temperature (12). In view of this, our BrainNet Europe interlabora-
tory study confirmed that indeed the quality of produced silver
stained sections varied significantly from center to center (2). Fur-
thermore, to our surprise, not only the quality of stained sections
varied, but also the quantitative results were not in full agreement
when assessing the hallmark lesions of AD. The concordance of
assessment of AD-related pathology following the instructions of
the CERAD classification was also reported to be less than optimal
(2, 13).
The study described above dealt with the assessment of hallmark
lesions in the neocortex without paying any significant attention to
their regional distribution. Already in 1977, Brun and colleagues
reported that in AD, the degeneration of the brain seemed to display
A From Khachaturian  Arch Neurol 1985; 42:1097–1105 
Age at death Number of lesions (magnification ×200), neuritic 
plaques (NP) and neurofibrillary tangles (NFT) in
a visual field  encompassing 1 sq mm < 50 50 – 65 66 – 75 > 75
>2–5       NP 
>2–5       NFT 
>8           NP 
some       NFT 
>10         NP 
some       NFT 
>15         NP 
or some   NFT 
firm
diagnosis
of AD 
very high 
degree of 
confidence
in diagnosis 
of AD 
diagnosis of 
AD diagnosis
of AD 
Note, if the subject displayed a positive clinical history of AD the criteria should be revised downward, suggestion 
only 50% as many lesions required 
B From CERAD / Mirra SS et al Neurology 1991; 41:479–486 
NP/100 × microscopic field density 
given in figures 
Age-related
plaque score 
Age-related
plaque score 
Neuropathological
diagnosis
       0                 none 0 0 0 C possible ADb definite AD 
   <3 sparse  C B A B possible ADb probable AD 
  3–6           moderate C C B A normal b possible ADa  
   >6             frequent C C C 0 normal a normal c 
 57>50–75 05< htaed ta egA Signs of 
dementia
not present present 
Note, NP = neocortical senile plaques of neuritic type, that is, those with thickened silver positive neurites; a = no 
histological evidence of  AD, b = plaques seen but no clinical history of dementia, c = history of dementia but 
there are no causative AD lesions; CERAD, the Consortium to Establish a Registry for Alzheimer’s Disease.
Figure 1. In both (A) and (B) the assessment
of Alzheimer’s disease (AD)-related pathology
is based primarily on the counts of
senile/neuritic plaques visualized by silver
stains. As the formation of pathology spans
decades and is also seen in the brains of
unimpaired subjects to obtain a definite
diagnosis of AD, both the age of the subject
and the clinical symptoms are of significance.
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primarily a temporo-parietal pattern of distribution (8). This dis-
tinctive distribution of AD-related pathology was later confirmed
and described in detail by Heiko and Eva Braak, this being cur-
rently referred to as Braak staging of AD-related NFT/neuropil
thread (NT) pathology, an assessment strategy that also has been
broadly accepted (3).
One of the problems with the Braak staging was that it was based
on the use of 100-mm-thick sections, which are not practical for use
in routine diagnostics, and thus, numerous modifications intro-
duced by various centers have been published (6). Furthermore, the
silver stains used to visualize NFT and NTs were recently shown
by our BrainNet Europe interlaboratory study to yield poor
reproducibility (2).
Even though the methods were known to be both laborious and
capricious, the currently commonly used consensus recommenda-
tions for post-mortem diagnosis of AD, launched by the National
Institute on Aging and Reagan Institute (NIA-RI) working group
in 1997, combined the two recommendations from 1991, CERAD
classification and Braak staging (Figure 2) (19). In these NIA-RI
recommendations, Braak stages (transentorhinal, limbic and iso-
cortical) are combined with the NP scores according to CERAD
(infrequent, moderate and frequent) resulting in a statement of
likelihood (low, intermediate, high) that dementia is due to
AD-related lesions. Thus, in NIA-RI recommendations, both the
extent and distribution of the dual pathology are important, that is,
there has to be both NFT and NP pathology. Additionally, it was
stated that in AD research centers, specific immunohistochemical
(IHC) stains should be used with the intention of correlating IHC
stained AD-related lesions with the conventional stains that dem-
onstrate these lesions.
Recently, it has been recognized that molecular classifications
represent the future for neuropathological diagnostic work (1).
Rather than using nonspecific chemical stains, IHC methods that
are based on precise molecular components are clearly preferable
when available.
Thus for the diagnosis of AD, one should assess the brains
regarding the occurrence of both hyperphosphorylated tau (HP-
tau) a protein which is found both in its soluble (pre-tangles and
NTs) and insoluble (NFT and NTs) forms and also b-amyloid (Ab)
protein which is found as variform plaques in parenchyma and is
present in cerebral amyloid angiopathy (CAA) in vessel walls.
Braak and colleagues reported in 2006 that Braak staging of
AD-related neurofibrillary lesions can also be carried out on IHC
stained conventional 5–7-mm-thick sections (6). The immunola-
beled AD-related neurofibrillary lesions vary, however, from those
seen when using the silver method, that is, Gallyas. The silver
method stains insoluble fibrillary NFT whereas the IHC method
labels the antigen, that is, HP-tau with both the soluble and
insoluble forms of the protein. Thus, when one compares the two
stainings, the extent of pathology is more pronounced when using
IHC methods and furthermore the predominant lesion in IHC
stained sections are NTs rather than NFT. Thus, the proposed
staging of AD-related neuronal pathology using IHC methodology
is primarily based on the regional distribution of stained NTs.
The benefits of IHC methods in the assessment of AD-related NT
pathology were also highlighted in the BrainNet Europe interlabo-
ratory study which revealed that both the quality of staining as well
as assessment of IHC stained sections yielded higher reproducibil-
ity when compared with silver stained sections (2).
In line with the above, the assessment of plaques applying IHC
methodology has been recommended and moreover, instead of
counting or assessing the Ab burden it has been proposed that the
presumed stepwise regional deposition of the Ab, that is, aggrega-
tion phases 1–5, should be assessed (17).
As far as we are aware, there has never been a thorough assess-
ment of the reproducibility of either neuronal or plaque-related
IHC labeled pathology in AD. The objective of this study was to
devise straightforward instructions for the assessment of IHC
labeled AD-related NT pathology that could be followed by any
neuropathologist, irrespective of his/hers familiarity with AD
cases. Another objective was to test the feasibility of using the
guidelines by conducting an interlaboratory experiment includ-
ing 25 independent evaluators routinely handling brain samples
obtained from subjects with neurodegenerative diseases.
MATERIAL AND METHODS
The general working order is summarized in Figure 3.
Sampling of material
Thirty cases were included that were collected in two centers and
the sampling of the blocks was carried out by two experienced
neuropathologists (IA, TA). The cases were selected based on the
Braak stage to which they were assigned by IA and TA after appli-
cation of silver stain. The goal was to include all severities of the
disease, that is, all the various stages of AD-related neurofibrillary
pathology. The samples were taken for the routine diagnostics
and obtained within a 10-year time span. The demographics of the
subjects are given in Table 1. The selection of anatomical regions to
be sampled was based on the requirements listed in current consen-
sus criteria (NIA-RI), and was also influenced by known general
practice among neuropathologists. The specimens included were
From NIA-RI, Neurobiol Aging 1997;S8:S1–2
Postmortem brain Likelihood that AD
pathological changes 
underlie dementia CERAD
plaque score
Braak
neurofibrillary stage 
High likelihood frequent stage V–VI 
Intermediate likelihood moderate stage III–IV 
stage I–II esraps doohilekil woL
Figure 2. The diagnosis of Alzheimer’s disease (AD) is given as a likelihood that both of the AD-related neuropathological lesions, neurofibrillary
tangles and neuritic plaques, are causative regarding clinical symptoms. NIA-RI = the National Institute on Aging and Reagan Institute; CERAD = the
Consortium to Establish a Registry for Alzheimer’s disease.
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the samples from middle frontal gyrus, inferior parietal lobule,
superior and middle temporal gyrus, occipital cortex including
calcarine fissure, posterior hippocampus at the level of lateral gen-
iculate nucleus and anterior hippocampus at the level of uncus.
A total of eight sets of 7-mm thick sections were produced from all
six brain areas of the 30 cases.
Immunohistochemistry
Five sets of sections were manually stained applying IHC method-
ology. Shortly, after rehydration, the sections were incubated over-
night at 4°C with a monoclonal primary antibody directed against
HP-tau (Innogenetics Br-03, clone AT8, dilution 1:500) and the
reaction product was visualized using the Zymed Lab-SA detection
system (Zymed, San Fransisco, CA, USA) with the use of Bio-
source Romulin AEC as chromogen (Biocare medical, Walnut
Creek, CA, USA).
Conventional stainings
Two sets were stained applying Gallyas and one set was stained
applying modified Bielschowsky silver impregnation technique.
Reference assessment
The members of the reference group (IA, TA, HK, HB, KdT)
jointly reassessed and staged all thirty cases around a multi-
headed microscope (Table 1). The cases were first assessed in
silver stains followed by a detailed analysis of the immunolabeled
sections. Each case was given a Braak stage based on the
assessment of Gallyas stained sections (3). The counts of NP
were evaluated on Bielchowsky silver impregnated sections as
described in the CERAD recommendations (12). When appli-
cable, that is, Braak stage in agreement with CERAD stage, each
case was given a NIA-RI likelihood statement (NIA-RI) (19). The
typical features seen in IHC stained sections for each stage were
agreed upon and these features were pinpointed in the final
instructions. During the assessment of 30 cases, it was noted that
the samples from middle frontal gyrus and inferior parietal lobe
did not alter the staging, and thus, these samples were excluded.
The samples included in this interlaboratory staging trial are
superior and middle temporal gyrus, occipital cortex including
calcarine fissure, posterior hippocampus at the level of lateral
geniculate nucleus and anterior hippocampus at the level of
uncus; they are shown in Figure 4.
The participating neuropathologists
Sampling of the material IA,TA
Selection of blocks to be included
The material included 30 cases sampled in two centers (Table 1)
Production of section IA
1. 5 sets of IHC/AT8 stained sections
2. 1 set of Bielschowsky silver stained sections
3. 2 sets of Gallyas silver stained sections
Primary assessment of the five circulating sets
Each participant assessed the section following the
given instructions. Result were shipped to the 
coordinator.
The reference group
IA,TA,HK,HB,KdT
5
2
1
Detailed instructions 
”How to stage AD-related immunolabelled
neuronal pathology” (Table 2, Figures 4,5,6).
Agreement between participating neuropathologists and the reference 
group when assessing immunolabelled AD-related lesions (Table 3)
RESULTS:
Staging of selected cases IA,TA,HK,HB,KdT :
Silver and immunohistochemically stained sections were
re-assessed jointly under multi-headed microscope and all cases
were staged. Agreement was reached on regions  to be included.
3
Design of instructions IA,TA,HK:
Detailed instructions in text, Table and Figure format were designed
and an assessment sheet was constructed (Figures 4,5,6 Tables 2)
4
All involved
Joint assessment
During a four hour consensus meeting held around a multi-
headed microscope all 30 cases with various stages of AD-
related neuronal degeneration were examined and discussed.
A table to be used when adjusting the primary assessments was 
constructed (Table 4)
6
The participating neuropathologists
Adjustment of primary assessments 
When needed, participants made readjustments in their
primary assessments. These results were shipped to
the coordinator (IA)
7
Agreement between participating neuropathologists and the reference
group when assessing immunolabelled AD-related lesions after
joint assessment (Table 5)
Additional instruction in table format
(Table 4)
Figure 3. Flowchart delineating the structure of the study. IHC = immunohistochemistry; AD = Alzheimer’s disease.
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Instructions
Detailed assessment instructions were written by three members
of the reference group (IA, TA, HK). The instructions included a
detailed description of the samples (Table 2A, Figure 4), a descrip-
tion of the pathology to be assessed (Table 2B, Figure 5), and exact
guidelines about the staging (Table 2C, Figure 6) which were based
on the distribution and load of immunolabeling in various neu-
roanatomical regions. It should be stressed, as has been previously
described (6) that the staging of the pathology was based on labeled
NTs rather than NFT.
BNE participant efforts
Twenty-five participants assessed and staged each case as
instructed. The results were recorded on the assessment sheets
which were sent to the coordinating center. These assessment
sheets included information on whether or not the participant had
identified the required neuroanatomical regions, the actual assess-
ment of labeled NTs and NFT and their designated staging of
the case.
Consensus meeting and joined assessment
A joint assessment of IHC labeled sections of cases ranging from
Braak stage 0 to VI was carried out around a multi-headed micro-
scope. The diagnostic features of each stage were discussed and
possible pitfalls were sought. Issues such as whether or not
all cases fulfilled staging requirements, that is, typical vs. atypical
cases were debated. In typical cases, the topography of labeled
NTs was in compliance with the Braak hierarchical sequence of
involvement of brain regions whereas in atypical cases this was not
seen. Furthermore, it was discussed whether there was a need for
modification of the originally issued instructions.
Revision of the original assessment
After the joint assessment, all participants were instructed to
adjust, if necessary, their originally designated stages. The final
stage was supposed to be given based on the results found in the
assessment sheets and following in detail the provided instructions.
To help the participants in this task, IHC stained sections of all
cases were scanned and a file with pictures was shipped to all
participants. In addition, each participant was asked to assess
whether or not the case was typical or atypical, that is, did or did not
the distribution pattern of IHC labeling seem to follow the pre-
dicted sequence described by Braak and Braak (3). These revised
assessments were then collected and the results were filed for
analysis.
Photomicrograph
Digital images were taken using a Leica DM4000 B microscope
equipped with a Leica DFC 320 digital camera.
RESULTS
The brain samples in this study were manually harvested by two
neuropathologists over quite an extensive time period, and thus
the sampling of the material resembles a real life scenario. As
expected, some variation in the levels of sectioning was seen.
However, this variation was not considered by the reference group,
to be of significance with respect to the staging of IHC/NT
pathology.
The results from the first round, prior to the consensus meeting,
obtained when 25 neuropathologists assessed and staged the IHC
stained sections of the 30 test cases adhering to the instructions are
listed in Table 3. The agreement with the reference assessment was
highest in the most severely affected cases (Braak stage VI-96%)
and lowest in the mildly affected cases (Braak stage I-33%), overall
59%. There was 81% agreement with respect to the reference
assessment for the isocortical Braak stages (V–VI), 68% for the
limbic stages (III–IV) and 43% with respect to the entorhinal
stages (I–II). In three cases (cases 3–5), the majority of the asses-
sors disagreed with the reference assessments. All these cases were
in stage I according to the reference assessment.
Most of the cortical regions (striatal, peristriatal and temporal
cortices) had been recognized with the exception of striatal and
peristriatal cortices in case 28. The greatest difficulties had been
encountered in identifying the outer layer of the entorhinal region
(cases 5, 10, 23, 25), the inner layer of the entorhinal region (case
30) and the temporo-occipital region (case 18).
The labeled neurons, pre-tangles and tangles were recognized by
all assessors whereas some variability was noted with regard to the
1 4 3 2
1
4 2 3
Figure 4. Gross view of the neuroanatomical
regions included. 1-occipital cortex including
calcarine fissure; 2-temporal cortex including
middle temporal gyrus and at least a part of
superior temporal gyrus, 3-anterior
hippocampus at the level of uncus and
4-posterior hippocampus at the level of
lateral geniculate nucleus.
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Table 2. Detailed instructions to be followed when assessing AD-related pathology (A) neuroanatomical regions (B) scoring of IHC labeling and
(C) staging of AD-related pathology. Abbreviations: IHC = immunohistochemistry; AD = Alzheimer’s disease; NT = neuropil threads.
(A) Harvested brain samples see also Figure 5 Main stage to be viewed
Section 1 The visual cortex including the calcarine
fissure
The section contains the striatal area (Brodmann area
17 = the primary visual cortex with macroscopically
identifiable band of Gennari) and para-/peristriate areas
(Brodmann area 18/19 = a six layered cortex area which
does not contain the band of Gennari).
AD stages VI and V
Section 2 The middle temporal gyrus The section occasionally includes a portion of the superior
temporal gyrus.
AD stage IV
Section 3 The anterior hippocampus and/or amygdala
at the level of uncus
The section contains the parahippocampal gyrus with
(trans-) entorhinal region and part of the
occipito-temporal gyrus (=fusiform gyrus).
AD stages III, II and I
Section 4 The posterior hippocampus at the level
of the lateral geniculate nucleus
The section includes posterior portions of the
parahippocampal gyrus with varying remnants of the
(trans-)entorhinal region or lingual gyrus. In most cases,
the adjoining occipito-temporal gyrus (=fusiform gyrus)
can also be seen.
AD stages II and III
Recommendation: Start viewing with the occipital section, followed by the temporal section, then move to the anterior section of the hippocampus,
and conclude with the hippocampal section taken at the level of the lateral geniculate nucleus
(B) Scoring of immunohistochemically labeled NTs, that is, density of IHC/AT8 positive NTs, see also Figure 6
+ Barely present at all at ¥100
++ Easily noted at ¥100
+++ Can be visualized even without a microscope
(C) Staging of AD-related neuronal pathology assessing IHC/AT8 stained NTs, see also Figure 6
Stage VI Severe involvement of occipital cortex Immunopositive NTs of at least moderate density (++ or +++) in layer V of the striate area.
This stage is so clearly visible that it may well be seen by the naked eye.
Stage V Immunopositive NTs of at least moderate density (++ or +++) in the superficial and deep
layers of the peristriate (and often also parastriate) area.
Stage IV Severe involvement of the middle temporal
gyrus
Immunopositive NTs of at least moderate density (++ or +++) in the superficial and/or deep
layers of the middle temporal gyrus.
Stage III Involvement of posterior hippocampus at
the level of the lateral geniculate nucleus
Immunopositive NTs of at least moderate density (++ or +++) in the outer and inner layers
of remnants of the entorhinal region, continuing into the neocortex of the adjoining
occipito-temporal gyrus.
Involvement of the anterior hippocampus
at the level of uncus
Immunopositive NTs of at least moderate density (++ or +++) in the superficial and deep
layers of the occipito-temporal gyrus. The immunopositivity in even a small region of the
occipito-temporal gyrus adjoining the transentorhinal region means that the specimen
should be diagnosed as stage III.
Stage II Involvement of posterior hippocampus at
the level of the lateral geniculate nucleus
Immunopositive NTs of at least moderate density (++ or +++) in the outer layers of
remnants of the entorhinal region and of at least low density (+ or ++ or +++) in the inner
layers of remnants of the entorhinal region.
Involvement of the anterior hippocampus
at the level of uncus
Immunopositive NTs of at least moderate density (++ or +++) in the outer layers of the
entorhinal region and of at least low density (+ or ++ or +++) in the inner layers of the
entorhinal region.
Stage I Involvement of the anterior hippocampus
at the level of uncus
Immunopositive NTs of at least low density (+ or ++ or +++) are localized in the
transentorhinal region.
Stage + Any section a) Single or few immunopositive cell bodies (tangles or pre-tangles) in any or more than
one region with distribution pattern that does not fit to one of the known tauopathies
and/or
b) NTs, either scattered or of low density (+) in any or more than one region and their
distribution pattern does not fit to one of the known tauopathies and
c) criteria for AD-related neuronal pathology stages 0, I to VI are not fulfilled.
Stage 0 All sections To award a diagnosis of stage, 0, all four sections must be IHC/AT8 negative.
Note, immunoreactive cell bodies (tangles or pre-tangles) may be seen in various hippocampal regions or in the neocortex at all stages and even in stage
+, but this should not influence the decision-making about the staging. The crucial feature is the presence or absence of IHC/AT8-labeled NTs.
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assessment of the extent of labeled NTs. Overall, out of the 30
cases, an absolute agreement regarding the labeling intensity of
NTs was reached in 57% for striatal cortex, in 50% for peristriatal
cortex and in 17% for temporal cortex. Even in the remaining
regions, no full agreement was reached and the assessment of
labeling of NTs most frequently varied from none to low or from
moderate to high. All possible ratings were given in three cases
when the specimens included striatal cortex (cases 26, 27, 29), in
five cases of peristriatal cortex (cases 25, 26, 27, 29, 30) and in one
case where there was temporal cortex (case 25). The tendency to
rate differently the extent of NTs was quite high in the regions
of anterior hippocampus. In 15 out of 30 cases, all possible ratings
were given for pathology present in the inner layer of the entorhinal
cortex. A similar trend was seen in the outer layer of the entorhinal
cortex (14/30), as well as in occipito-temporal gyrus and transen-
torhinal cortex (11/30 in both).
Most of the assessors participated in the consensus meeting
where there was a joint assessment of all cases. It became evident
that most of the assessors had not evaluated the stained sections
with the naked eye (as recommended in the original instructions),
though that is clearly useful method when assessing density of
labeled NTs. High to moderate labeling of NTs is visible with
naked eye inspection. Furthermore, it was noted that some asses-
sors had found it difficult to follow the instructions. Thus some
modifications, that is, clarifications of the original instructions
were needed, and consequently, a new table was devised (Table 4).
All cases were scanned and a file with pictures of the four stained
sections was created to support the adjustment of stages if needed.
The results obtained when 25 neuropathologists adjusted their
staging based on previously given assessments (ie, assessment
sheets) and with the help of the scanned pictures are found in
Table 5. Only in three cases, all in stage I according to the reference
group (cases 3, 4 and 5), did the assessors mostly disagree with the
reference assessment, whereas in general, the agreement with the
reference assessment was 65%. In particular, the over-assessments
seen in the original staging that primarily was based on assessment
of NFT rather than NTs had mostly disappeared. The best results
were obtained with stages where cortical regions were affected
(stage VI = 100%, stage V = 81% and stage IV = 84%). The
poorest results (42%) were noted for stage I which does require
good familiarity with some neuroanatomical regions such as the
entorhinal and transentorhinal regions. The agreement with the
reference assessment was 91% for the isocortical stages (V–VI),
72% for the limbic stages (III–IV) and 50% for the entorhinal
stages (I–II).
The reference group considered 28 out of the 30 included cases
as typical with respect to the distribution of NT pathology, that is,
distribution of pathology as expected for an AD stage. One case
(case 1) lacked any pathology and in one case (case 2) only scat-
tered labeled NFT were seen. In agreement with this, most cases
¥ 100
¥ 200
A - low =  + B - moderate = ++ C - high = +++
Figure 5. Density of AT-8 immunopositive neuropil threads at magnifications ¥ 100 and ¥ 200. A. Low (+), that is, immunoreactive (IR) structures are
barely noted at low magnification. B. Moderate (++), that is, IR structures are easily seen at both magnifications. C. High (+++), that is, IR structures are
seen even without the microscope. Sections are taken from occipital cortex.
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were assessed as being typical AD cases also by most of the asses-
sors, but there were some exceptions. Cases 8, 9, 10, 13 and 14
were considered as atypical by 30% of the assessors. In one of these
“atypical” cases, the stages assigned varied from + to stage IV. In
addition, cases assessed by most assessors as “+” (cases 3, 4 and 5)
were considered as atypical, that is, the lesions were not considered
to display a typical distribution pattern described for AD.
DISCUSSION
It has recently been recognized that molecular classifications must
be used in neuropathological diagnostics and thus IHC methods
that are based on precise molecular components are recommended
when available (1). With respect to AD, the assessment of occur-
rence of HP-tau seen in pre-tangles, tangles, neurites and NP and
the assessment of the occurrence of Ab in the parenchyma as vari-
form plaques or as CAA is the diagnostic mode of choice. To our
knowledge, there has never been a thorough evaluation of the
reproducibility of the assessment of IHC labeled HP-tau or Ab
pathology in subjects with AD. This report deals with the repro-
ducibility of evaluation when 25 neuropathologists assessed the
HP-tau-related pathology in 30 subjects with various degrees of
severity of AD-related neurofibrillary pathology.
The most important and also the most difficult task when staging
lesions that progress in a continuous rather than stepwise manner
is to define the cut off points, that is, the most typical features of
hallmark lesions for each proposed stage. If one wishes to avoid the
situation where the assessor has the impression that a case displays
features seen in adjoining stages, the assessment instructions have
to be described succinctly but clearly, even if they are based on
arbitrary decisions. The emphasis should be on the most notable
feature for each stage, that is, there should be a clear separation on
one hand of what is or can be seen and on the other hand what is
requested to be seen in each separate stage. The latter specification
Braak stage I
Block 1 Block 2                         Block 3                            Block 4
Occipital Temporal Hippocampus Hippocampus
cortex cortex anterior posterior
Braak stage II
Braak stage III
Braak stage IV
Braak stage V
Braak stage VI
Figure 6. Scanned immunohistochemically
stained sections applying AT8 antibody.
Section from: Block 1 – occipital cortex
including calcarine fissure; Block 2 – temporal
cortex including middle temporal gyrus and at
least a part of superior temporal gyrus; Block
3 – anterior hippocampus at the level of uncus;
and Block 4 – posterior hippocampus at the
level of lateral geniculate nucleus. The regions
are given from left to right in the suggested
order of assessment. The arrowheads indicate
borders for the relevant neuroanatomical
regions for each given stage: Braak I –
transentorhinal region; Braak II – entorhinal
region; Braak III – temporo-occipital gyrus;
Braak IV – temporal cortex; Braak V –
peristriatal cortex; and Braak VI striatal cortex.
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“what is required to be seen” is the pathognomonic feature of
a given stage.
Instructions for the assessment in this trial were designed with
three major parameters in mind. First, the region of significance
in each stage was defined, that is, stage I – transentorhinal region,
stage II – entorhinal region, stage III – temporo-occipital cortex,
stage IV – temporal cortex, stage V and VI – occipital cortex.
Second the type of lesion to be assessed was defined, that is, the NT
network, with the third parameter being the intensity of staining of
NTs, that is, the labeling had to be intense, that is, notable with
Table 3. Stages of AD-related neurofibrillary
pathology when 25 neuropathologists have
assessed immunohistochemically stained
sections. The stage assessed by the reference
group is given in bold. Abbreviations:
ABS% = absolute agreement in percentage,
that is, number of evaluation staged equally by
the reference group and the 25 participating
assessors; AD = Alzheimer’s disease.
Case 0 + I II III IV V VI ABS%* ABS%† ABS%‡ ABS%§
1 13 11 1 52 42 42
2 17 8 32
3 3 14 8 32
4 3 16 5 1 20
5 2 16 3 3 1 12 33
6 4 13 7 1 52
7 2 6 12 4 1 48
8 3 5 10 6 1 40 43
9 2 6 12 4 1 48
10 2 6 15 1 1 60 51
11 2 3 17 2 1 68
12 1 12 10 1 1 48
13 4 1 11 6 2 1 44
14 5 8 10 2 40
15 2 5 14 3 1 56 59
16 4 16 4 1 64
17 19 5 1 76 62
18 6 17 2 68 68
19 9 14 2 56
20 9 15 1 60
21 4 19 1 1 76
22 5 19 1 76
23 24 1 96 83
24 1 1 19 4 76
25 18 7 72
26 17 8 68 63
27 12 13 48 81
28 3 22 88
29 25 100 96
30 25 100
*Percentage for each individual case. †Percentage for all cases within a Braak stage. ‡Percentage
for cases within transentorhinal, limbic and isocortical stages. §Percentage for all.
Table 4. Staging of Alzheimer’s disease-related neuronal pathology on the basis of density and regional distribution of IHC/AT8 immunopositive
neuropil threads. The density is scored on a four step scale 0-none; +-some; ++-moderate; +++ severe (see also Figure 6). Abbreviations:
IHC = immunohistochemistry.
Section number Region Stage I Stage II Stage III Stage IV Stage V Stage VI
Occipital cortex Area 17 0–+ 0–+ 0–+ 0–+ 0–+ ++–+++
Area (18)/19 0–+ 0–+ 0–+ 0–+ ++–+++ ++–+++
Temporal cortex 0–+ 0–+ 0–+ ++–+++ ++–+++ ++–+++
Anterior hippocampus Occipito-temporal gyrus 0–+ 0–+ ++–+++ ++–+++ ++–+++ ++–+++
Entorhinal region Outer layers 0–+ ++–+++ ++–+++ ++–+++ ++–+++ ++–+++
Inner layers 0–+ +–+++ ++–+++ ++–+++ ++–+++ ++–+++
Transentorhinal region +–+++ ++–+++ ++–+++ ++–+++ ++–+++ ++–+++
Posterior hippocampus Occipito-temporal gyrus 0–+ 0–+ ++–+++ ++–+++ ++–+++ ++–+++
Remnants of the entorhinal
region
Outer layers 0–+ ++–+++ ++–+++ ++–+++ ++–+++ ++–+++
Inner layers 0–+ +–+++ ++–+++ ++–+++ ++–+++ ++–+++
In stages I to VI various numbers of IHC/AT8-labeled neurons are seen, but the presence of IHC/AT8-positive neurons is not used as a diagnostic
criterion. The hallmark lesion for each Braak stage is given in bold.
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naked eye inspection. In summary, there are two minimal require-
ments for the assessment of AD-related IHC labeled NT pathology:
(i) adequate sampling of tissue blocks; and (ii) equally important
is high quality IHC staining.
Twenty-five neuropathologists assessed 30 cases following
instructions devised for this trial and reached a general agreement
of 59%, ranging from 42% to 96% for different stages of progres-
sion of NT pathology, with the highest agreement achieved in
the most severely affected cases. This agreement was improved to
65%, ranging from 42% to 100%, after a consensus meeting
including a joint assessment of cases and a revision of the
instructions.
One of the major oversights noted during the first assessment
was that the labeled NFT were considered to be of significance
even though the evaluators had been instructed otherwise. It
seemed that it was difficult for a neuropathologist to stage a case as
being in stage II–III, if NFTs were observed in temporal or occipi-
tal cortices. Thus the concordance of the assessments improved,
simply by making the appropriate revision, that is, when staging
IHC labeled section, the emphasis should be on the labeled NTs
rather than on NFT.
As predicted, when assessing the highest stages of AD-related
NT pathology, the agreements were close to excellent. The excel-
lent agreement regarding AD-related NT pathology in stages
IV–VI following our instructions indicates that indeed AD-related
IHC labeled NT pathology is comparable even when assessed by
different neuropathologists. In other words, a subject evaluated as
being in stage V in one center will receive the same stage assess-
ment in another center. This information is of importance not only
from a diagnostic point of view but also regarding research situa-
tions. The high concordance in assessments makes it possible
to combine post mortem brain material obtained from various
centers. This will make it possible to conduct large-scale biochemi-
cal and other studies including hundreds of well-characterized
samples. Furthermore, extensive screening of possible risk factors
including hundreds, if not thousands, of neuropathologically veri-
fied AD patients can be carried out.
More disturbingly in the mildly affected cases, the agreement
was poorer. One explanation for the poor agreement in stages I–III
might be the prerequisite of good familiarity with the neu-
roanatomy of the hippocampal region, and particularly, the anterior
part of hippocampus.
The lack of familiarity with the neuroanatomy of anterior hip-
pocampus is probably due to the fact that most diagnostic neuro-
pathologists tend to routinely sample posterior hippocampus at the
level of the geniculate body. Minor parts of anterior hippocampus
might be found in the often routinely sampled section of basal
forebrain that also includes the amygdaloid nucleus.
Table 5. Stages of AD-related pathology when
25 neuropathologists adjusted their original
assessment after consensus meeting. The
stage assessed by the reference group is
given in bold. Abbreviations: ABS% = absolute
agreement in percentage, that is, number of
evaluation staged equally by the reference
group and the 23 participating assessors;
AD = Alzheimer’s disease.
Case 0 + I II III IV V VI ABS%* ABS%† ABS%‡ ABS%§
RZ146 13 11 1 52 42 42
RZ176 17 8 32
RZ92 6 11 8 32
RZ165 5 13 7 28
01–104 2 15 7 1 28 42
97–147 3 15 7 60
02–277 2 6 15 2 60
00–255 5 14 6 56 50
01–74 1 3 17 4 68
02–96 2 9 13 1 52 57
02–149 3 1 3 16 2 64
070–00B 2 1 11 10 1 44
093–02B 1 3 15 4 2 60
RZ57 4 6 14 1 56
03–170 3 3 14 5 56 65%
RZ239 6 17 2 68
97–284 1 23 1 92 67
02–031 5 18 1 1 72 72
01–178 8 17 68
RZ147 1 9 15 60
04–025 1 7 16 1 64
RZ181 11 14 56
02–020 25 100 84
RZ163 24 1 96
03–212 23 2 92
RZ153 22 3 88 81
RZ162 16 9 64 91
02–310 25 100
RZ66 25 100 100
99–156 25 100
*Percentage for each individual case. †Percentage for all cases within a Braak stage. ‡Percentage
for cases within transentorhinal, limbic and isocortical stages. §Percentage for all.
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Recent reports, have, however, emphasized that the transentorhi-
nal and entorhinal regions seen in the anterior parts of hippocam-
pus are of importance when assessing aged subjects and patients
with mild memory impairment and thus a section taken from ante-
rior part of hippocampus is recommended to be sampled routinely
(3, 4, 6). Furthermore, with respect to AD pathology, one has to be
able to identify the transentorhinal region in order to assess stage I,
the entorhinal region in order to assess stage II, and the temporo-
occipital regions have to be identified if one wishes to assess stage
III. It is noteworthy that in the posterior parts of hippocampus,
sampled at the level of lateral geniculate body, only remnants of
transentorhinal cortex might be seen making the assessment of
stage I virtually impossible. Similarly, the outer layer of entorhinal
cortex might well be lost, complicating the assessment of stage II.
In general, areas such as transentorhinal cortex as well as entorhi-
nal cortex with its upper and inner layers might easily be over-
looked if the sections are not optimally harvested. It is noteworthy
that reliable identification particularly of the transentorhinal region
in the section of anterior hippocampus or identification of the rem-
nants of transentorhinal region in the section of posterior hippoc-
ampus in routine 5–7-mm-thick sections might sometimes be diffi-
cult even for a trained neuroanatomist or neuropathologist.
Moreover, it should be noted that the identification of hippocam-
pal regions might have been easier for the assessors if all of the
cases had been harvested by the same neuropathologist and within
a shorter time span (sampling more homogenous). Sampling of
brain specimens is, however, manual work, and thus, a wide range
of variation in sectioning levels, is generally seen.
In some of our cases when only mild pathology was seen, the
evaluator encountered difficulties in clearly stating, that the case
represented stage I. Thus, the assessor tended to label these cases
as “+”, that is, mild immunoreactivity present but criteria for
AD-related neuronal degeneration are not fulfilled. This was prob-
ably due to the fact that they had not reliably identified the transen-
torhinal region. These cases were reassessed by the reference group
and it was noted that indeed the transentorhinal and/or remnants of
transentorhinal region required to be identified in stage I, were not
always easily and reliably identified in the 7-mm-thick IHC stained
sections. When these cases that were assessed by the majority as
being “+” cases were excluded (case 3, 4, 5) the overall agreement
reached a level of 67%.
An interrater-intrarater study assessing staging of AD-related
NFT pathology has already been carried out in 1997 (14). The
agreement between the six examiners including Heiko Braak, was
almost perfect, kappa statistic values reaching values above 0.9. It
is noteworthy, that the study was carried out on 100-mm-thick silver
stained section, a method not practical under routine working con-
ditions. Furthermore, it is not clear whether there were differences
in the assessment of low vs. high stages. Consequently, comparison
of results from 1997 with the results obtained in our study carried
out applying IHC and 7-mm-thick sections and including 25
observers is not possible.
The poor agreement found in our study regarding mild involve-
ment of AD pathology and employing 7-mm-thick sections empha-
sizes how important it is that when carrying out assessment of
normal aged patients with mild cognitive impairment, that the sam-
pling of tissue for neuropathological assessment is standardized.
This is important if one intends to identify the transentorhinal
region in 5–7-mm-thick routine sections. Furthermore, in research
settings, it would probably be advisable that rather than collecting
assessments carried out by different assessors, a reassessment of
cases should be carried out, preferably by two independent neuro-
pathologists well-familiarized with the anatomical structure of the
anterior part of the hippocampus. In addition, when assessing AD
cases one should always conduct a parallel assessment of the
concomitant Ab pathology. Instead of merely confirming that Ab
aggregates are seen, a staging of Ab aggregates into phases based
on regional distribution should be carried out, as has been
described by Thal and colleagues in 2002 (17). The evaluation of
the regional distribution of both NTs and Ab might significantly
influence the final assessment results.
Recently, McKee and colleagues reported that the visual asso-
ciation cortex, Brodmann area 19 (parastriatal cortex), was affected
in the preclinical stage of AD (11). The area they assessed was
described to be located laterally from calcarine cortex, striatal
cortex (area 17) and peristriatal cortex (area 18). They reported that
they had examined 25 neurologically unimpaired subjects in Braak
stages ranging from I to IV whereas the CERAD NP counts ranged
from none to frequent. Interestingly, in 13 of these cases, IHC
labeled NFT were seen in area 19 ranging from one NFT/20¥ field
to >10NFT/field (¥200 magnification), whereas only occasional
NFT were seen in area 17/18. The results of McKee and colleagues
challenge the general view described by Heiko and Eva Braak that
AD lesions develop according to a recognized and predictable
sequence. When assessing our 30 cases, many of them were in the
transentorhinal and limbic stages, IHC labeled NFT were occasion-
ally (10 out of 24 cases) seen in areas 17/18, in agreement with
results of McKee and colleagues. It is noteworthy that in Braak
stages V–VI, in sections of 7-mm thickness, a net of labeled NTs
rather than NFT were seen even with the naked eye in areas 17 and
18. The visual association area, area 19, was in some of our cases
partly included but unfortunately, not to the same extent as in the
study by McKee and colleagues. Thus, we are unable to adequately
compare IHC labeling of NFT in our 30 cases with the results
obtained by McKeen and colleagues. Furthermore, the section
thickness (7 mm vs. 50 mm) might also alter IHC labeling of NFT
seen in our 30 cases when compared with their 41 subjects. Their
results are, however, of great interest, as the visual association
cortex is certainly easier to harvest and identify when compared
with some of the neuroanatomical regions in the anterior hippoc-
ampus. Additional studies are urgently needed to confirm these
results.
A predictable sequence of progression of lesions facilitates a
staging strategy that can be followed when assessing neurodegen-
erative lesions (3, 5, 17). It should, however, be remembered
that the proposed predictable sequence of development of some
common brain lesions has recently been challenged; for example,
the results of McKee and colleagues are difficult to reconcile with
the traditional sequence of neuronal pathology in AD (11). Interest-
ingly, with regard to a-synuclein (aS) pathology, the alteration in
the predictable progressions of pathology has been proposed to be
due to concomitant AD pathology (16, 22). In line with the above,
in familial cases carrying the presenilin-1 mutation, studies with
positron emission tomography agent Pittsburgh compound-B, indi-
cate that Ab deposition begins in the striatum rather than in cortex
(10). Furthermore, it has been reported that the apolipopreotein E
e4 allele modifies the deposition of Ab in vessel walls (15, 18).
These recent reports regarding NFT, Ab, andaS pathology indicate
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that the progression of pathology does not always follow the pro-
posed sequence and that alternative routes of progression might
exist, perhaps because of genetic predisposition, concomitant dis-
eases, brain pathologies or environmental factors. These alterations
need to be recognized as they might significantly alter the assess-
ment results.
Neuropathologists need detailed diagnostic instructions as was
already shown by the EURAGE study (7). Furthermore, the
methods used when visualizing lesions of interest should be repro-
ducible (2) and preferably be specific in that they have a molecular
basis. In addition, the methods should be applicable for routine
working situations. Based on our results, reliable assessment of one
of the culprits in AD namely HP-tau containing lesions in an inter-
laboratory setting can be reached when the instructions are simple
and clear, the IHC labeling is robust and the lesions are substantial,
that is, they have spread to isocortical structures. In contrast, in
subjects where only mild subtle lesions can be seen (AD-related
NT pathology in stage I–III), it is recommended that reassessment
of lesions by two independent assessor should be carried out, espe-
cially in a research setting.
It should also be kept in mind that biological events are not
always strict and thus the proposed sequential development of
pathology might be altered by a variety of factors and thus influ-
ence the staging results.
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